Inflammatory Bowel Disease (IBD) Treatment Market Size, Industry Analysis Report, Regional Outlook, Application Potential, Price Trends, Competitive Market Share & Forecast, 2021 – 2027
Report ID: GMI4305
Inflammatory Bowel Disease Treatment size is expected to grow significantly from 2019 to 2025.
Increasing prevalence of inflammatory bowel disease, new product approvals and developments are some of the key factors propelling the growth of the IBD treatment market. According to the Center for Disease Control and Prevention, about 3 million that 1.3% of U.S. adult was diagnosed with inflammatory bowel disease in 2015. The increasing prevalence for IBD is propelling the development of new therapy to treat the disease and that is anticipated to boost the market growth globally.
To develop novel drug therapy, various biopharmaceutical companies are significantly making investment R&D activities that are expected to propel the growth of inflammatory bowel disease treatment market during the forecast period. Moreover, currently, there is a large number of pipeline products in different stages of clinical approvals which are likely to commercialize during the forecast period. For instance, AstraZeneca and Allergan are together developing MEDI2070 interleukin-23 monoclonal antibody against ulcerative colitis and Crohn’s Disease. The MEDI2070 is currently in phase II b of the clinical trial for moderate to severe Crohn’s disease and in phase II for ulcerative colitis. The Pfizer's PF-00547659 and Celgene’s Ozanimod are in phase II and phase III clinical trials for Crohn’s Disease and ulcerative colitis, respectively. The approval of these drugs is expected to generate immense revenue growth of the IBD treatment market globally. However, the growing availability of biosimilar of key IBD drugs may create interferences for established market players.
Biologics treatment therapy is estimated to account for significant market share in the inflammatory bowel disease treatment market in 2018. Rising the adoption of biologics such as TNF inhibitors, promising drug pipeline, and high research and development spending to develop biologics are some of the major factors propelling the growth of the segment in the inflammatory bowel disease treatment market.
The ulcerative colitis segment should witness significant growth in the inflammatory bowel disease treatment market during the forecast period. The presence of a strong product pipeline for ulcerative colitis along with ongoing research is anticipated to drive segmental growth. For instance, in March 2019, Phase III UNIFI study for STELARA by Johnson & Johnson has shown positive results in adults suffering from severe and moderate ulcerative colitis. The introduction of pipeline drugs into the market during the forecast period is expected to generate immense growth opportunities for the segment in the market.
The hospital pharmacy segment is estimated to hold a dominating share in the inflammatory bowel disease treatment market in 2018. The increasing number of hospital admission owing to the growing prevalence of ulcerative colitis and Crohn's disease. The well-established infrastructure of hospitals along with ease of availability of treatment is also boosting the growth of the segment in the IBD treatment market during the forecast period.
North America's inflammatory bowel disease treatment market accounts noteworthy revenue share in 2018 and will register substantial growth during the forecast period. Well-established healthcare facilities, high incidence of IBD, and high risk of lifestyle-related risk factors are some of the prominent factors propelling the growth of the market in the region. According to, in the U.S. about 70,000 new cases of inflammatory bowel disease are diagnosed every year. The increasing patient population with IBD along with ongoing research is in the region expected to drive the growth of the market by introducing new therapy during the forecast period. Furthermore, increasing geriatric population, high government support, high awareness about inflammatory bowel disease treatment, in the region will spur the regional growth.
Some of the major players operating in the inflammatory bowel disease treatment industry include Pfizer, Johnson & Johnson, Takeda Pharmaceutical Company, Celltrion Healthcare, CELGENE, AbbVie, COSMO PHARMACEUTICALS, UCB, Innovate Biopharmaceuticals, and Gilead Sciences. The market for inflammatory bowel disease is characterized by regional expansion strategies, acquisitions and partnerships, and a rise in the number of product launches and growing dominance of the leading players. For instance, in 2017, Janssen Biotech, has announced a strategic agreement to develop and market PTG-200, an oral IL 23 receptor with Protagonist Therapeutics, Inc. for the treatment of inflammatory bowel disease. The partnership will boost product development and that is expected to drive market growth significantly.
Inflammatory Bowel Disease Treatment Market By Drug Class, 2014-2025 (USD Million)
Inflammatory Bowel Disease Treatment Market By Disease Indication, 2014-2025 (USD Million)
- Ulcerative Colitis
- Crohn’s Disease
Inflammatory Bowel Disease Treatment Market By Distribution Channel, 2014-2025 (USD Million)
- Hospital Pharmacy
- Retail Pharmacy
- Online Pharmacy
The above information is provided for the following regions and countries:
- North America
- Asia Pacific
- Latin America
- Middle East and Africa
- Saudi Arabia
- South Africa
- Johnson & Johnson
- Takeda Pharmaceutical Company
- Celltrion Healthcare
- COSMO PHARMACEUTICALS
- Innovate Biopharmaceuticals
- Gilead Sciences
What Information does this report contain?
Customize this Report
Our Market Research Reports Include:
- Market snapshot
- Market Segmentation
- Value Chain Analysis
- Growth Dynamics
- Potential Market Opportunities
- Regulatory Overview
- Technology Evolution
- Innovation & Sustainability
Benefits of Association
Data Coverage & Quality
GMI reports provide the most comprehensive coverage of any focus industry, ensuring a holistic and deep understanding of the market, along with actionable and granular data. We also take pride in our commitment to quality and strive to ensure that our clients get their moneys worth.
Client Trust & Security
GMI maintains strict code of conduct as a business and is committed to ensure that the privacy and trust of our clients are always maintained. As an organization, we also strive to be fully compliant with privacy laws, PCI and information security guidelines.
Our customers rely on us to produce accurate, reliable and timely information. Service orientation is a key mission for us as an organization; our process is guided by the desire to ensure that our clients are provided the best possible solutions in optimal timeframe. GMI stands by its commitment to service, providing timely assistance in both pre-sales and post-sales support for our clients.